← Research ProtocolsTesamorelin
STUDIED EXPOSURE MAP / 2007
Tesamorelin
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED CONTROLLEDNEW ENGLAND JOURNAL OF MEDICINESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
2 mg
once daily · SC · 26 weeks
Context: This exposure belongs to the defined trial population and endpoint. It is not generalized to other populations or purposes.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / NEW ENGLAND JOURNAL OF MEDICINE
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2007
01 / DESIGNMulticenter · randomized · placebo-controlled
02 / POPULATION / MODEL412 patients with HIV and abdominal fat accumulation
03 / ROUTESubcutaneous · daily
04 / TIMEFRAME26 weeks
05 / PRIMARY QUESTIONPercent change in visceral adipose tissue by CT
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
GHRH analogue and metabolic research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.